WASHINGTON, D.C., February 26, 2026
The U.S. Food and Drug Administration (FDA) has granted approval to Hernexeos (zongertinib) for the treatment of adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) tyrosine kinase domain activating mutations, marking the second approval under the Commissioner’s National Priority Voucher (CNPV) Pilot Program. The application, filed on January 13, 2026, received a final decision within 44 days, underscoring the agency’s accelerated review capabilities under the newly launched priority framework designed to expedite therapies addressing critical national health needs.
Accelerated Review Under National Priority Voucher Program
Hernexeos was proactively granted a National Priority Voucher in November 2025 based on preliminary data demonstrating strong clinical activity. The CNPV pilot program provides enhanced communication pathways, rolling review mechanisms, and shortened regulatory timelines for products targeting significant unmet medical needs. According to the FDA, the program is structured to support innovative therapies that improve patient outcomes, promote domestic pharmaceutical manufacturing, and enhance affordability. This latest approval reflects the agency’s broader effort to reduce administrative delays while maintaining rigorous safety and efficacy standards. FDA Commissioner Marty Makary, M.D., M.P.H., emphasized that the program seeks to eliminate idle review periods and accelerate access to transformative treatments for patients with life-threatening conditions.
Strong Clinical Response in HER2-Mutant Lung Cancer
Clinical data submitted to the FDA showed that 76% of previously untreated patients experienced a substantial reduction in tumor size, representing a marked improvement over historical response rates of 30–45% under standard-of-care regimens. Lung cancer remains the leading cause of cancer-related mortality in the United States, with an estimated 226,650 new cases and 124,730 deaths in 2025, highlighting the urgent need for targeted therapies in molecularly defined patient populations. Hernexeos specifically targets tumors with HER2 (ERBB2) activating mutations, a subset of NSCLC patients for whom treatment options have historically been limited. The drug previously received accelerated approval in August 2025 for patients who had received prior systemic therapy; this new approval expands its indication to first-line treatment settings, significantly broadening access to eligible patients.
Advertisement
Regulatory Designations and Safety Profile
Hernexeos was granted both Breakthrough Therapy Designation and Priority Review, reflecting the FDA’s recognition of its potential to offer substantial clinical benefit over existing therapies. The accelerated approval pathway requires continued post-marketing evaluation to confirm long-term clinical benefit. Serious adverse reactions associated with Hernexeos include hepatotoxicity, left ventricular dysfunction, interstitial lung disease/pneumonitis, and embryofetal toxicity, while commonly reported side effects include diarrhea, rash, fatigue, nausea, musculoskeletal pain, and upper respiratory tract infection. The approval was granted to Boehringer Ingelheim Pharmaceuticals, Inc., reinforcing the role of global pharmaceutical manufacturers in advancing precision oncology treatments through expedited regulatory channels.
The decision highlights the evolving landscape of precision oncology, biomarker-driven drug development, and accelerated regulatory pathways, demonstrating how targeted therapies can rapidly move from clinical evidence submission to market authorization under structured priority programs. As the FDA continues implementing the National Priority Voucher Pilot Program, industry stakeholders will closely monitor its impact on future oncology approvals, regulatory timelines, and innovation incentives across the pharmaceutical sector.
Source: U.S. Food and Drug Administration (FDA) press release
